Sorcero’s Contrarian Path to Growth: Why They Rejected the MVP Playbook in Life Sciences

The “move fast and break things” mantra doesn’t work when your customers spend billions bringing life-saving drugs to market. In a recent Category Visionaries episode, Sorcero founder Dipanwita Das revealed why they chose to spend three years building their product before launch – a decision that challenged conventional startup wisdom but ultimately led to 400% year-over-year growth.

Understanding the Market’s DNA

When Sorcero started in 2018, Das identified three critical challenges in life sciences: “First, of course, data is everywhere. There’s a lot of it. It’s also spread out and really hard to handle. The data unification challenge is extremely real,” she explains.

But it was the second observation that shaped their development strategy: “We’re building the same thing over and over again. With every new campaign, with every new group we’re supporting, with every new disease we’re working on, we’d start everything again and build again.”

This insight revealed why the typical MVP approach would fail. Medical affairs teams weren’t looking for incremental improvements – they needed comprehensive solutions that could handle complex, regulated data at scale.

The Three-Year Investment

Instead of rushing to market, Sorcero spent three years testing their approach across multiple verticals. “In 2021, in 2020, people were a lot more skeptical about buying a product without seeing proof of that product being, well, fully baked,” Dipanwita notes. “We didn’t have the privilege of throwing around mockups and doing a very immature iteration and having any material customer adoption.”

This patience allowed them to build something their market actually needed: a platform that could unify data across sources, create scalable workflows, and measure impact in ways that weren’t previously possible.

Validation Through Growth

The market validated their approach immediately. After launching their first product in early 2021, Sorcero expanded to a suite of three products with 400% year-over-year growth. Their platform now helps medical affairs teams work 92% faster while gaining insights that were impossible to surface manually.

The success stems from understanding that in life sciences, trust and capability matter more than speed to market. “Our customers have traditionally bought services and have depended on expert consultants to be able to do their job,” Dipanwita explains. This insight led them to build partnerships rather than trying to disrupt existing workflows.

Building for Impact

For Das, the ultimate validation comes from impact stories: “We collect stories, and we have had a few of our investors come and tell us personal stories of how they used Sorcero to craft and to change and advocate for more appropriate treatment for themselves.”

This focus on real-world impact over rapid iteration has positioned Sorcero to become what Dipanwita envisions as “the command center for Life Sciences product commercialization, supporting accelerated adoption of life changing drugs.”

For founders targeting regulated industries, Sorcero’s journey offers a compelling alternative to the MVP playbook. Sometimes, the fastest path to scale is taking the time to build something worth scaling.